Global Tauopathies Treatment
Global Tauopathies Treatment

Tauopathies Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales), Diseases (Alzheimer’s disease, Frontotemporal Degeneration, Other Neurodegenerative Diseases) Players and Region - Global Market Outlook to 2026

Tauopathies Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 221 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Tauopathies are neurodegenerative problems characterised with the aid of an unusual buildup of tau protein in the brain. Tauopathy is a team of neurodegenerative ailments characterised via the aggregation of tau protein in the human intelligence into neurofibrillary or gliofibrillary tangles. Tangles are generated when the microtubule protein tau is hyperphosphorylated, main it to detach from microtubules and structure insoluble aggregates. Pick disease, modern supranuclear palsy, corticobasal degeneration, and argyrophilic grain disorder are solely a few of the tau ailments that have until now been researched.This growth is primarily driven by Rising prevalence of dementia diseases.

Globally, a noticeable market trend is evident Rising research and development to produce new medicines. Major Players, such as Avanir Pharmaceuticals, Inc., (United States), Otsuka Pharmaceutical Co., Ltd., (Japan), AB Science (France), Cortice Biosciences (United States), REGENXBIO Inc. (United States), Aquinnah Pharmaceuticals (United States), Neurimmune (Switzerland), Biogen (United States), TauRx (United Kingdom), Sellas (United States) and Catalent Inc., (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
The adoption of strategies such as mergers & acquisitions and by major industry players is expected to contribute to the growth of the global tauopathies treatment market. For instance, in January 2020, Biogen completed acquisition of Pfizer’s asset of Parkinson’s and Alzheimer’s for USD 710 million. The aim of the company behind this acquisition is to develop CK1 inhibitor CNS-penetrate for patients with behavioural and neurological symptoms in numerous neurological and psychiatric diseases.

Market Drivers
  • Rising prevalence of dementia diseases

Market Trend
  • Rising research and development to produce new medicines

Restraints
  • Shortage drugs for tauopathies
  • Lack of knowledge regarding tauopathies treatment

Opportunities
Rising growth of clinical trial approvals
Challenges
Difficult to detect tauopathies in patients

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Tauopathies Treatment Study Sheds Light on
— The Tauopathies Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Tauopathies Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Tauopathies Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Tauopathies Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Tauopathies Treatment Market?
Companies that are profiled in Global Tauopathies Treatment Market are Avanir Pharmaceuticals, Inc., (United States), Otsuka Pharmaceutical Co., Ltd., (Japan), AB Science (France), Cortice Biosciences (United States), REGENXBIO Inc. (United States), Aquinnah Pharmaceuticals (United States), Neurimmune (Switzerland), Biogen (United States), TauRx (United Kingdom), Sellas (United States) and Catalent Inc., (United States) etc.

3. What is Tauopathies Treatment Market?
Tauopathies are neurodegenerative problems characterised with the aid of an unusual buildup of tau protein in the brain. Tauopathy is a team of neurodegenerative ailments characterised via the aggregation of tau protein in the human intelligence into neurofibrillary or gliofibrillary tangles. Tangles are generated when the microtubule protein tau is hyperphosphorylated, main it to detach from microtubules and structure insoluble aggregates. Pick disease, modern supranuclear palsy, corticobasal degeneration, and argyrophilic grain disorder are solely a few of the tau ailments that have until now been researched.
Report Objectives / Segmentation Covered
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

By Diseases
  • Alzheimer’s disease
  • Frontotemporal Degeneration
  • Other Neurodegenerative Diseases

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of dementia diseases
    • 3.3. Market Challenges
      • 3.3.1. Difficult to detect tauopathies in patients
    • 3.4. Market Trends
      • 3.4.1. Rising research and development to produce new medicines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tauopathies Treatment, by Distribution Channel, Diseases and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tauopathies Treatment (Value)
      • 5.2.1. Global Tauopathies Treatment by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacy
        • 5.2.1.2. Retail Pharmacy
        • 5.2.1.3. Online Sales
      • 5.2.2. Global Tauopathies Treatment by: Diseases (Value)
        • 5.2.2.1. Alzheimer’s disease
        • 5.2.2.2. Frontotemporal Degeneration
        • 5.2.2.3. Other Neurodegenerative Diseases
      • 5.2.3. Global Tauopathies Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Tauopathies Treatment (Price)
  • 6. Tauopathies Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Avanir Pharmaceuticals, Inc., (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co., Ltd., (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AB Science (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cortice Biosciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. REGENXBIO Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aquinnah Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neurimmune (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. TauRx (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sellas (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Catalent Inc., (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Tauopathies Treatment Sale, by Distribution Channel, Diseases and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tauopathies Treatment (Value)
      • 7.2.1. Global Tauopathies Treatment by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacy
        • 7.2.1.2. Retail Pharmacy
        • 7.2.1.3. Online Sales
      • 7.2.2. Global Tauopathies Treatment by: Diseases (Value)
        • 7.2.2.1. Alzheimer’s disease
        • 7.2.2.2. Frontotemporal Degeneration
        • 7.2.2.3. Other Neurodegenerative Diseases
      • 7.2.3. Global Tauopathies Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Tauopathies Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tauopathies Treatment: by Distribution Channel(USD Million)
  • Table 2. Tauopathies Treatment Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 3. Tauopathies Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 4. Tauopathies Treatment Online Sales , by Region USD Million (2015-2020)
  • Table 5. Tauopathies Treatment: by Diseases(USD Million)
  • Table 6. Tauopathies Treatment Alzheimer’s disease , by Region USD Million (2015-2020)
  • Table 7. Tauopathies Treatment Frontotemporal Degeneration , by Region USD Million (2015-2020)
  • Table 8. Tauopathies Treatment Other Neurodegenerative Diseases , by Region USD Million (2015-2020)
  • Table 9. South America Tauopathies Treatment, by Country USD Million (2015-2020)
  • Table 10. South America Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 11. South America Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 12. Brazil Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 13. Brazil Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 14. Argentina Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 15. Argentina Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 16. Rest of South America Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 17. Rest of South America Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 18. Asia Pacific Tauopathies Treatment, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 20. Asia Pacific Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 21. China Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 22. China Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 23. Japan Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Japan Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 25. India Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 26. India Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 27. South Korea Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 28. South Korea Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 29. Taiwan Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 30. Taiwan Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 31. Australia Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 32. Australia Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 35. Europe Tauopathies Treatment, by Country USD Million (2015-2020)
  • Table 36. Europe Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 37. Europe Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 38. Germany Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 39. Germany Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 40. France Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. France Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 42. Italy Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. Italy Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 44. United Kingdom Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 45. United Kingdom Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 46. Netherlands Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Netherlands Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 48. Rest of Europe Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Europe Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 50. MEA Tauopathies Treatment, by Country USD Million (2015-2020)
  • Table 51. MEA Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. MEA Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 53. Middle East Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 54. Middle East Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 55. Africa Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. Africa Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 57. North America Tauopathies Treatment, by Country USD Million (2015-2020)
  • Table 58. North America Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 59. North America Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 60. United States Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 61. United States Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 62. Canada Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 63. Canada Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 64. Mexico Tauopathies Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. Mexico Tauopathies Treatment, by Diseases USD Million (2015-2020)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Tauopathies Treatment: by Distribution Channel(USD Million)
  • Table 78. Tauopathies Treatment Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 79. Tauopathies Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 80. Tauopathies Treatment Online Sales , by Region USD Million (2021-2026)
  • Table 81. Tauopathies Treatment: by Diseases(USD Million)
  • Table 82. Tauopathies Treatment Alzheimer’s disease , by Region USD Million (2021-2026)
  • Table 83. Tauopathies Treatment Frontotemporal Degeneration , by Region USD Million (2021-2026)
  • Table 84. Tauopathies Treatment Other Neurodegenerative Diseases , by Region USD Million (2021-2026)
  • Table 85. South America Tauopathies Treatment, by Country USD Million (2021-2026)
  • Table 86. South America Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 87. South America Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 88. Brazil Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 89. Brazil Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 90. Argentina Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 91. Argentina Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 92. Rest of South America Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 93. Rest of South America Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 94. Asia Pacific Tauopathies Treatment, by Country USD Million (2021-2026)
  • Table 95. Asia Pacific Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 96. Asia Pacific Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 97. China Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 98. China Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 99. Japan Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 100. Japan Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 101. India Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 102. India Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 103. South Korea Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 104. South Korea Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 105. Taiwan Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 106. Taiwan Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 107. Australia Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 108. Australia Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 109. Rest of Asia-Pacific Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 110. Rest of Asia-Pacific Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 111. Europe Tauopathies Treatment, by Country USD Million (2021-2026)
  • Table 112. Europe Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 113. Europe Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 114. Germany Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 115. Germany Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 116. France Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 117. France Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 118. Italy Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 119. Italy Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 120. United Kingdom Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 121. United Kingdom Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 122. Netherlands Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 123. Netherlands Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 124. Rest of Europe Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of Europe Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 126. MEA Tauopathies Treatment, by Country USD Million (2021-2026)
  • Table 127. MEA Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 128. MEA Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 129. Middle East Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 130. Middle East Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 131. Africa Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 132. Africa Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 133. North America Tauopathies Treatment, by Country USD Million (2021-2026)
  • Table 134. North America Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 135. North America Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 136. United States Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 137. United States Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 138. Canada Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 139. Canada Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 140. Mexico Tauopathies Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 141. Mexico Tauopathies Treatment, by Diseases USD Million (2021-2026)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tauopathies Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 5. Global Tauopathies Treatment: by Diseases USD Million (2015-2020)
  • Figure 6. South America Tauopathies Treatment Share (%), by Country
  • Figure 7. Asia Pacific Tauopathies Treatment Share (%), by Country
  • Figure 8. Europe Tauopathies Treatment Share (%), by Country
  • Figure 9. MEA Tauopathies Treatment Share (%), by Country
  • Figure 10. North America Tauopathies Treatment Share (%), by Country
  • Figure 11. Global Tauopathies Treatment share by Players 2020 (%)
  • Figure 12. Global Tauopathies Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Tauopathies Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Avanir Pharmaceuticals, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 16. Avanir Pharmaceuticals, Inc., (United States) Revenue: by Geography 2020
  • Figure 17. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue: by Geography 2020
  • Figure 19. AB Science (France) Revenue, Net Income and Gross profit
  • Figure 20. AB Science (France) Revenue: by Geography 2020
  • Figure 21. Cortice Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 22. Cortice Biosciences (United States) Revenue: by Geography 2020
  • Figure 23. REGENXBIO Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. REGENXBIO Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Aquinnah Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. Aquinnah Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 27. Neurimmune (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Neurimmune (Switzerland) Revenue: by Geography 2020
  • Figure 29. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 30. Biogen (United States) Revenue: by Geography 2020
  • Figure 31. TauRx (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. TauRx (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Sellas (United States) Revenue, Net Income and Gross profit
  • Figure 34. Sellas (United States) Revenue: by Geography 2020
  • Figure 35. Catalent Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 36. Catalent Inc., (United States) Revenue: by Geography 2020
  • Figure 37. Global Tauopathies Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Tauopathies Treatment: by Diseases USD Million (2021-2026)
  • Figure 39. South America Tauopathies Treatment Share (%), by Country
  • Figure 40. Asia Pacific Tauopathies Treatment Share (%), by Country
  • Figure 41. Europe Tauopathies Treatment Share (%), by Country
  • Figure 42. MEA Tauopathies Treatment Share (%), by Country
  • Figure 43. North America Tauopathies Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Avanir Pharmaceuticals, Inc., (United States)
  • Otsuka Pharmaceutical Co., Ltd., (Japan)
  • AB Science (France)
  • Cortice Biosciences (United States)
  • REGENXBIO Inc. (United States)
  • Aquinnah Pharmaceuticals (United States)
  • Neurimmune (Switzerland)
  • Biogen (United States)
  • TauRx (United Kingdom)
  • Sellas (United States)
  • Catalent Inc., (United States)
Additional players considered in the study are as follows:
Bristol-Myers Squibb Company (United States) , Chronos Therapeutics Limited (United Kingdom) , SK Biopharmaceuticals Co., Ltd. (South Korea)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation